Rewiring the Addicted Brain: Circuits-Based Treatment for Addiction

GRAZIELLA MADEO1,2 AND ANTONELLO BONCI²,3,4

1Novella Fronda Foundation, Human Science and Brain Research Piazza Castello, 16-35141 Padua, Italy
2Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
3Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
4Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Correspondence: antonello.bonci@nih.gov

The advent of the noninvasive brain stimulation (NIBS) technique has paved the way for neural circuit–based treatments for addiction. Recently, evidence from both preclinical and clinical studies has evaluated the use of transcranial magnetic stimulation (TMS) as a safe and cost-effective therapeutic tool for substance use disorders (SUDs). Indeed, repetitive TMS impacts on neural activity inducing short- and long-term effects involving neuroplasticity mechanisms locally within the target area of stimulation and the network level throughout the brain. Here, we provide an integrated view of evidence highlighting the mechanisms of TMS-induced effects on modulating the maladaptive brain circuitry of addiction. We then review the preclinical and clinical findings suggesting rTMS as an effective interventional tool for the treatment of SUDs.

Drug addiction is a chronic relapsing brain disorder, characterized by compulsion to seek and take the drug, loss of control in limiting the intake despite harmful consequences, and negative emotional state when access to the drug is prevented (American Psychiatric Association 2013). The term addictions is now encompassed by the term substance use disorders (SUDs), since the DSM-5 consider substance abuse and substance dependence as one diagnostic construct in which the severity of SUDs ranges from mild to moderate depending on how many criteria apply (American Psychiatric Association 2013). Compelling evidence has shown that the initial exposure to substance abuse exerts a reinforcing effect by activating reward circuits in the brain mainly encoding for a voluntary behavior, whereas the repeated drug administration progressively impairs brain functions by altering the ability to self-control over drug-seeking and -taking behaviors (Volkow et al. 2016). Classically, an SUD is conceptualized as a complex three-stage recurring cycle, worsening over time and involving neuroplastic changes in three major circuits: (i) reward-basal ganglia system in the binge/intoxication stage; (ii) extended amygdala and stress response system dysfunctions related to the withdrawal negative affect stage; and (iii) prefrontal cortex (PFC) and executive function systems related to the preoccupation/anticipation stage (Goldstein and Volkow 2002; George and Koob 2010). Progress in understanding the neurobiology of addiction has been made through the study of either animal models or brain-imaging studies in addicted individuals (Kenny et al. 2018). Translating the preclinical findings into clinical applications to set an effective therapeutic intervention for addiction still presents a challenge. Cognitive behavioral therapy, motivational interviewing, contingency management, and spiritual engagement are used as preventive and treatment strategies to reduce substance use with modest and short-term effectiveness. A better understanding of the neurobiological mechanisms underlining SUDs has allowed us the development of pharmacological compounds based on the receptor system implicated. Ideally, the technological advances in drug development should enable the design of drugs that can specifically target the receptor subtypes involved in the pathophysiology of SUDs. However, the pharmacotherapy for SUDs is still very limited in terms of efficacy and tolerability. Indeed, despite the elegant and precise modulation of distinct neurotransmitter systems, these compounds are not able to limit their site of action to a specific brain area or circuit. The broad action of these compounds, strictly related to the likelihood of having side effects, is particularly evident when targeting the glutamatergic or GABAergic neurotransmitter system. As a result, whereas for some SUDs there are Food and Drug Administration (FDA)-approved medications (e.g., naltrexone and acamprosate for alcohol use disorder; naloxone for opiate use disorder), for others, like cocaine or methamphetamine, there are no FDA-approved interventions. Recently, there has been a growing interest designing neural circuit–based therapeutic interventions for individ-
uals with SUDs. Findings from preclinical studies have shown a causal relationship between frontostrital circuit activity and drug-related behaviors (Chen et al. 2013a; Stefanik et al. 2013). Moreover, clinical studies have shown that activity in the same frontostrital circuits are useful as biomarkers for predicting vulnerability to relapse in several SUDs (Hong et al. 2009; Sinha 2011; Bunce et al. 2013). Thus, the hypothesis that applying brain stimulation to those circuits could potentially revert some of the drug-induced neuronal adaptations and reduce addictive behaviors has been investigated in both preclinical and pilot clinical studies. Basic science studies showed that the activation of infralimbic brain areas, such as the PFC, via either electrical or optogenetic stimulation, results in a reduction of drug intake in rats (Levy et al. 2007; Chen et al. 2013a). In humans, brain stimulation of targeted brain regions can be achieved noninvasively by using transcranial magnetic stimulation (TMS). TMS is a noninvasive brain stimulation technique that delivers fluctuating magnetic field pulses through the skull into the brain, where electrical currents are generated, and thus the neuronal activity modulated (Hallett 2000). Repetitive TMS (rTMS) pulses in sequences at specific parameters can induce long-term changes within the neuronal circuits and influence specific behaviors. In this report, we discuss the TMS-induced changes in neuroplasticity and connectivity, possibly underlining its long-term effects, as well as the advantages and drawbacks of this technique. We describe the preclinical findings obtained using optogenetics in rodents, demonstrating that the stimulation of prefrontal cortical circuits reverts the compulsive seeking of drugs. Then, we link these observations to those from imaging and neurophysiologic studies in humans where rTMS has been shown to be effective in reducing drug craving and drug intake. Finally, we highlight the new advances and the conceptual gaps that need to be filled by future preclinical and clinical studies.

NEUROBIOLOGY OF TRANSCRANIAL MAGNETIC STIMULATION (TMS)-INDUCED EFFECTS

TMS is a noninvasive physical method based on the electromagnetic induction principle, in which fluctuating magnetic field pulses are delivered and, passing through the skull, reach the targeted brain areas (Hallett 2000). The magnetic field generates electric currents able to induce changes of neuronal excitability in the brain area where the coil is positioned over the scalp. TMS is a very flexible tool, as different stimulation parameters can induce distinct neuronal mechanisms. TMS pulses can be delivered as single pulse (spTMS), as a couple of pulses (paired-pulses, pp-TMS), or as a repetitive sequence of pulses at specific frequencies (rTMS) or patterned with a train of pulses sequence and a specific intertrain interval (theta-burst stimulation [TBS]) (Hallett 2000; Rossi et al. 2012). Depending on stimulation parameters, TMS can induce short- or long-term effects and modulate the neuronal activity by eliciting a facilitative or suppressive effect on cortical excitability. Although spTMS and ppTMS are mainly used to study timing-dependent neuronal processes lasting fraction of seconds (e.g., changes in the magnitude of motor evoked potentials [MEPs]), rTMS and TBS have been associated with long-lasting changes within neuronal circuits influencing behavioral responses and possibly offering a therapeutic option. These TMS-induced aftereffects are critically dependent on stimulation parameters, such as frequency and/or pattern of stimulation, stimulation intensity, and anatomical loci (Hallett 2000). In general, rTMS at low frequency (≤1 Hz) determines a suppressive effect on neuronal activity reducing cortical excitability, whereas higher frequencies (5–25 Hz) typically have a facilitatory effect, increasing neuronal activity and cortical excitability (Hallet, 2000; Diana et al. 2017). rTMS neuronal effects persist for at least several minutes and can influence behavioral response. The TMS behavioral effects can be partially state-dependent, meaning that the cortical activity before or during TMS may influence whether TMS facilitates or suppresses behavioral responses (Silvanto et al. 2008). In humans TMS effects on brain physiology can be studied in the primary motor cortex (M1) by recording the elicited MEPs from peripheral muscles and by using electroencephalography (EEG) and functional neuroimaging techniques (e.g., positron emission tomography, functional magnetic resonance) (Paus and Barrett 2004; Siebner et al. 2009; Ilmoniemi and Kičić 2010). Relevant additional information come from both in vitro (Edgley et al. 1997; Jackson et al. 2016) and in vivo (Cirillo et al. 2017) studies using computational modeling, pharmacological approaches, and circuit-specific modulation (Ilmoniemi et al. 1999; Cohen et al. 2004; Silvato et al. 2008; Salvador et al. 2011). All together these studies have shown that TMS causes direct effects activating the targeted brain area under the coil and indirect effects of remote cortical and subcortical areas anatomically connected to the primary activation site (Ilmoniemi et al. 1997; Bestmann et al. 2004; Paus and Barrett 2004; Di Lazzaro et al. 2012).

TMS Factors and Mechanisms for Neuroplasticity

Animal, human neuroimaging, and electromyographic (EMG) studies have provided considerable insights into the mechanistic bases of TMS. EMG studies in which spTMS was used to stimulate the motor cortex as a model region allowed the assessment of neuroplastic changes within corticospinal excitability. Delivering rTMS at high frequency (5–25 Hz) has a facilitatory effect on motor corticospinal excitability, whereas low-frequency inhibits cortical excitability. Similarly, intermittent TBS and continuous TBS can facilitate or suppress motor cortical excitability, respectively (Pascual-Leone et al. 1994). Both animal and human studies have shown that one of the hypothesised mechanisms underlying the long-term neuroplastic changes induced by TMS is an LTP- or LTD-like phenomenon at the synaptic level ( Pell et al. 2011; Hanlon et al. 2015; Cirillo et al. 2017; Diana et al. 2017). The occurrence of LTP or LTD is dependent on the stimulation parameters, such as frequency, stimulation intensity and duration, anatomical loci, coil shape, and modulation of
the glutamatergic postsynaptic signaling (Huang et al. 2005; Labruna et al. 2016; Cirillo et al. 2017). Although the detailed mechanisms are still poorly understood, there is a general agreement that high-frequency stimulation (10–20 Hz) rTMS or iTBS with a duration between 7 and 20 min over the motor cortex produces a rapid postsynaptic influx of calcium ions and a long-lasting increase in the amplitude of the MEP, suggesting there are LTP-like effects on cortical excitability (Pascual-Leone et al. 1994; Cárdenas-Morales et al. 2010). Conversely, low-frequency rTMS (1 Hz) or cTBS with a duration between 9 and 15 min elicits a decrease of MEP amplitude, inducing LTD-like effects (Pascual-Leone et al. 1994; Cárdenas-Morales et al. 2010). Although these observations could explain the differences between high- and low-frequency rTMS, or intermittent and continuous TBS, the underlying downstream mechanisms are more complex and still require further investigation (Tigges et al. 2016). Duration, number of sessions, and number of pulses are also important factors for clinical TMS effects. Some studies focusing on patients with depression have shown that longer stimulation protocols (e.g., doubling the number of rTMS pulses or number of sessions) can induce better clinical effects (Hadley et al. 2011; Modirrousta et al. 2018; Schulze et al. 2018). Nevertheless, other studies suggest that longer duration or greater intensity does not necessarily increase the clinical efficacy. Indeed, facilitatory aftereffects are converted to suppressive when doubling the duration of iTBS or increasing the intensity (Gamboa et al. 2010; Doeltgen and Ridding 2011). Stimulation parameters are not only the important factors to determine the directionality of neuroplasticity changes. Several studies have shown how the baseline cortical activation state influences the stimulation aftereffects of TMS (Silvanto et al. 2008). From a homeostatic plasticity perspective, any external intervention preceding or following the stimulation can determine the direction of synaptic plasticity because of the regulatory mechanisms that allow the system to maintain an equilibrium condition (Silvanto et al. 2008; Karabanov et al. 2015; Cirillo et al. 2017). It is clear that a number of interacting mechanisms may underlie the variability of cortical excitability changes. Preclinical studies on cellular and animal models, even not reproducing the exact human brain condition, have provided relevant details regarding the TMS-induced effects at a cellular level. One of the proposed mechanisms involves the simultaneous activation of presynaptic and postsynaptic sites similar to classical NMDA receptor–dependent Hebbian plasticity (Vlachos et al. 2012; Lenz et al. 2015). Synaptic transmission changes are paralleled to morphological modification involving spine formation and pruning, as observed in entorhinal and hippocampal slice culture (Lenz et al. 2015). It is likely that multiple mechanisms at different levels play a role in rTMS plasticity; acute synaptic events can trigger long-term changes through dendritic spine remodeling and neurotransmitter signaling regulation (Chervyakov et al. 2015; Lanza et al. 2015; Lenz et al. 2015). Finally, nonsynaptic mechanisms may also add further complexity to this scenario. Indeed, activation of neurotrophic factor signaling (Zhang et al. 2007; Cheeran et al. 2008; Chervyakov et al. 2015), modulation of glial cells (Chen et al. 2013b; Chervyakov et al. 2015; Cirillo et al. 2017), and epigenetic modification (Etévé et al. 2015) can play a role in determining the long-term aftereffects of rTMS.

**REWIRING BRAIN CIRCUITRY FOR SUDs**

Neurobiological studies of SUDs have clearly shown the relationship between the increase of neuronal activity within the meso-cortico-limbic system and the acute reinforcing and rewarding effects of stimulant drugs (Volkow et al. 1996; Everitt and Robbins 2005). As stimulant drug, cocaine induces a rapid increase of dopamine level within the meso-cortico-limbic circuit (Volkow et al. 1996) and changes in glutamatergic and GABAergic systems that critically intervene in sustaining addictive behaviors (Feltstein and See 2009; Diana et al. 2017). The meso-cortico-limbic system includes dopamine projections from neurons in the ventral tegmental area (VTA) to nucleus accumbens (NAc), amygdala, hippocampus, and cortical areas, such as the PFC and the anterior cingulate cortex (ACC) (Goldstein and Volkow 2002; Diana et al. 2017). Chronic exposure to drugs, including cocaine, induces long-term neuroadaptations because of the repeated hyperactivity of dopaminergic transmission and results in alterations of cortical neurotransmission and excitability (Koob and Volkow 2010), involving frontocortical areas. Neuroimaging studies of addicted individuals showed alterations within key frontal brain regions (Goldstein and Volkow 2011), including the dorsolateral prefrontal cortex (DLPFC) that regulates goal-directed behavior, the orbitofrontal cortex (OFC) related to decision-making, impulsivity, and behavioral inhibition, and the ACC involved in error detection (Volkow et al. 2003; Jovanovski et al. 2005; Goldstein and Volkow 2011; McHugh et al. 2013). Abnormalities within the PFC-striato-thalamic circuits are believed to play a central role in compulsive drug-seeking behavior and relapse. Neuropsychological findings suggest that frontal circuitry dysfunction reduces the ability to inhibit behavioral responses in favor of drug-seeking. Targeting dysfunctions in the meso-cortico-limbic system may contribute to design effective therapeutic interventions for reverting addicted-related behaviors, such as craving, compulsive drug use, and relapse. Here, we describe findings coming from both preclinical and clinical studies supporting the therapeutic role of rTMS in treating cocaine addiction.

**Evidence from Preclinical Studies**

Preclinical models have certainly disentangled some of the cellular and molecular mechanisms by which TMS exerts neurophysiological effects potentially supporting the clinical improvements of addictive symptoms. Several animal studies have explored the possibility of using TMS or TMS-like protocols, targeting the frontal brain region, as a nonpharmacological intervention for addiction.
Repeated brain stimulation of the PFC has been found to affect cocaine addiction-related behaviors in rodent models (Feil and Zangen 2010). These effects can be related to the increase of dopamine release in the NAc following rTMS protocols (Strafella et al. 2001; Kanno et al. 2003; Feltenstein and See 2009). Indeed, although drug consumption is associated with an increased level of dopamine within reward circuitry, dopaminergic activity is reduced during the withdrawal stage. This hypodopaminergic tone has been related to the occurrence of craving and relapse (Nestler 2005; Kalivas and O’Brien 2008). By using in vivo neurochemical techniques, such as microdialysis, it has been shown that acute rTMS over frontal brain regions significantly increased dopamine release in the dorsal hippocampus, dorsal striatum, and PFC (Kanno et al. 2003). Therefore, the increase in dopamine level induced by repeated brain stimulation can reduce craving in individuals under withdrawal conditions (Blum et al. 2008). Our understanding of the neural circuitry regulating drug-seeking and cue-induced reinstatement has significantly advanced via development in optogenetics (Diana et al. 2017). Using this technique, specific neuronal populations, infected with channelrhodopsin or halorhodopsin, can be selectively activated or inhibited through exposure to different light frequencies (Berndt and Deisseroth 2015). Thus, in vivo optogenetic stimulation of the PFC prevented the compulsive seeking behavior in rodent models of cocaine self-administration, whereas inhibition of the same region led to an increase in cocaine-seeking (Chen et al. 2013a; Stefanik et al. 2013; Diana et al. 2017). Despite the limitations of animal studies, these findings provide the neurobiological basis for a therapeutic role of rTMS-driven PFC stimulation in treating cocaine addiction (Levy et al. 2007; Amiaz et al. 2009; Diana et al. 2017).

### Evidence from Human Studies

The long-lasting modulatory effects of TMS have been shown to be promising as therapeutic interventions for a large variety of neurological and psychiatric disorders. DLPFC has been selected as the stimulation target in most addiction studies so far. Specifically, rTMS evaluating its therapeutic use in addiction has targeted most often the left DLPFC with excitatory stimulation. The large majority of these studies have evaluated the effects in reducing spontaneous and cue-induced craving for several substances of abuse. In Table 1, clinical studies investigating the therapeutic potential of TMS are detailed for the major classes of substances of abuse. Starting from preclinical observations that optogenetic stimulation of prefrontal areas could revert the compulsive cocaine-seeking in rats, a pilot open-label clinical study was conducted by our group (Terraneo et al. 2016). Multiple sessions of high-frequency rTMS of the left DLPFC were reported to reduce spontaneous craving for cocaine and increased the abstinence rates, as assessed by the number of cocaine-free drug tests (Terraneo et al. 2016). Further pilot clinical studies report that rTMS of the left DLPFC is effective in reducing craving and intake (Politi et al. 2008; Bolloni et al. 2016; Rapinesi et al. 2016). As mentioned earlier, the mechanisms by which rTMS of DLPFC is potentially useful for reducing symptoms related to cocaine addiction are linked to the modulatory effects on neurotransmitter systems (Volkow et al. 2004; Diana et al. 2017). Dopamine signaling is a key candidate to explain the rTMS effects. Neuroimaging studies showed that rTMS of frontal brain regions causes an increase of dopamine levels within basal ganglia (Strafella et al. 2001, 2003) and cortical areas (Cho and Strafella 2009), confirming preclinical findings. These studies showed an increase of dopamine efflux in frontal brain areas, NAc, and hippocampus (Kanno et al. 2003). Although direct stimulation of basal ganglia complex is less likely, as the intensity of the induced magnetic field decays with distance from the coil (Hallett 2000), rTMS can cause secondary activation of subcortical areas anatomically connected (direct or indirect) to the DLPFC (Ilmoniemi et al. 1997; Bestmann et al. 2004; Paus and Barrett 2004). Left DLPFC has been the targeted area for other studies investigating the therapeutic potential of rTMS for SUDs. Open and blinded clinical studies reported that high-frequency rTMS is effective in reducing spontaneous and cue-induced craving in smokers (Johann et al. 2003; Li et al. 2013; Dinur-Klein et al. 2014). Another relevant factor in determining the clinical effects of rTMS is drug consumption. Some studies indicated that active rTMS results in a substantial reduction in number of drinks per day in individuals with alcoholism and in number of cigarettes smoked and level of nicotine addiction in smokers (Eichhammer et al. 2003; Cecchini et al. 2015; Addolorato et al. 2017). So far, only a few studies have investigated the rTMS effects targeting the right DLPFC. One study reported a reduction in craving following multiple sessions of rTMS (Mishra et al. 2015), whereas no anticraving effects were reported by another study (Herremans et al. 2015). Additionally, bilateral DLPFC stimulation reduced spontaneous craving for alcohol (Kling et al. 1990). In summary, the studies conducted so far suggest that rTMS of the DLPFC can reduce drug-seeking and -taking behaviors but do not provide a clear answer on durability of rTMS efficacy or whether there are better stimulation parameters for rTMS protocols. Further clinical work in larger samples with controlled trial designs is needed to investigate the potential role of rTMS in addiction.

### SUMMARY AND FUTURE DIRECTIONS

The ability to modulate addiction-related behaviors in a circuit-specific manner through noninvasive brain stimulation techniques, such as rTMS, is a powerful alternative for cocaine use, as no FDA-approved pharmacotherapy is available. An increasing number of studies report that rTMS stimulation of the DLPFC is able to reduce craving to several substances of abuse. However, clinical studies investigating the therapeutic potential of rTMS for addictive disorders are still limited by small sample size, design variability, and lack of a sham-controlled group. Other sources of variability across the studies include differences in stimulation parameters, clinical assessment question-
| Studies                        | N     | Participants                                   | Design                                                                 | Outcomes measures                                                                                     | Number of sessions | Stimulation site | F (Hz)/% MT | Total pulses per session | Effects                                                                 | Adverse events                  |
|-------------------------------|-------|-----------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------|-------------------|-------------|--------------------------|------------------------------------------------------------------------|---------------------------------|
| Nicotine                      | 14    | Nicotine dependent; motivated to quit smoking | Randomized, double-blind, sham-controlled, crossover trial          | Craving measured by VAS; number of cigarettes smoked during an ad libitum smoking phase after treatment | 4 (2 Ac; 2 S)      | Left DLPFC       | 20/90%      | 1000         | Significant reduction in smoking in the rTMS group. No effect on craving | Mild headache in two cases after active stimulation                    |
| Johann et al. 2003            | 11    | Nicotine dependent; motivated to quit smoking | Randomized, double-blind, sham-controlled, crossover trial          | Craving measured by VAS                                                                                         | 2 (1 Ac and 1 S)   | Left DLPFC       | 20/90%      | 1000         | Significant reduction in craving after the real rTMS                  | Not reported                      |
| Amiaz et al. 2009             | 48    | Nicotine dependent; >20 cigarettes/day; motivated to quit smoking | Randomized, double-blind, sham-controlled, crossover trial (four subgroups: active versus sham rTMS/ smoking-related versus neural picture cues). Ten daily sessions followed by a 4-wk maintenance phase | Urine cotinine levels; Craving measured by VAS and sTCQ; dependence evaluated by FTND | Ten daily sessions | Left DLPFC       | 10/100%     | 1000         | Significant reduction in cue-induced craving, cigarette smoking and dependence when subjects received exposure to smoking cues followed by rTMS | One dropout due to not clearly specified adverse effects |
| Rose et al. 2011              | 15    | Cigarette smokers; >20 cigarettes/day         | Randomized crossover open-label study. At the beginning of each session, subjects smoked a cigarette. One hour later, they underwent rTMS concurrently during exposure to (1) neutral (2) smoking cues (3) smoking a cigarette. | Craving measured by Shiffman–Jarvik Questionnaire; Cigarette evaluation questionnaire; | 3 (1 Hz SFG; 10 Hz SFG; 1 Hz motor cortex) | SFG or motor cortex (side not specified) | 1 and 10 Hz/90% | Greater number of pulses for the 10 Hz condition | Combination of smoking cues exposure and 10 Hz SFG rTMS increased craving | Not reported                      |
| Hayashi et al. 2013           | 10    | Moderate to heavy smokers                    | Randomized, double-blind, sham-controlled crossover study           | Craving measured by VAS after cue or neutral exposure; BOLD-contrast imaging;                                | 4 (2Ac; 2S) paired with two different conditions (delayed versus immediate cigarette availability) | Left DLPFC         | 1/NS        | 1800         | Significant reduction in craving for smoking during the “immediate availability” condition and attenuation of concomitant fMRI signal in the medial orbitofrontal cortex | Not reported                      |
| Studies                  | N    | Participants                                      | Design                                                                 | Outcomes measures                                                                 | Number of sessions | Stimulation site | F (Hz)/% MT | Total pulses per session | Effects                                                                 | Adverse events                                                                 |
|-------------------------|------|--------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------|-------------------|---------------|--------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Li et al. 2013          | 16   | Nicotine dependent; ≥10 cigarettes/day; not treatment seeking | Randomized, double-blind, sham-controlled, crossover trial. 2 h abstinence before the session | Craving measured by computerized 100-point scale QSU-Brief                        | 2 (1 Ac and 1 S)  | Left DLPFC        | 10/100%       | 3000                     | Significant reduction in craving in the active group; positive correlation between the effect of rTMS and the severity of the dependence | Mild discomfort at the start of stimulation                                      |
| Trojak et al. 2015      | 37   | Nicotine dependent; treatment seeking            | Randomized, double-blind, sham-controlled study between-subject study. rTMS was associated to nicotine replacement therapy | Continuous abstinence from smoking was based on self-report and verified by an expired carbon monoxide concentration; craving measured by VAS, sTCQ and QSU | 10 sessions across 2 wk | Right DLPFC        | 1/120%        | 3600                     | Greater abstinence rate at the end of 2 wk following active rTMS. No effect on craving | Not reported                                                                      |
| Dinur-Klein et al. 2014 | 115  | Nicotine dependent; >20 cigarettes/day; treatment seeking | Double-blind, placebo-controlled, randomized clinical trial. Three different stimulation condition (1, 10 Hz, sham) with or without exposure to alcohol cues | Cigarette consumption evaluated by measuring urine cotinine levels and recording participants’ self-reports; dependence evaluated by FTND; craving measured by sTCQ | 13 sessions (1, 10 Hz or sham) | Bilateral DLPFC and insular cortex | 1 and 10 Hz/120% | 1 Hz: 600 pulses; 10 Hz: 990 pulses | 10 Hz rTMS combined with exposure to smoking cues reduced craving, cigarette consumption and dependence | Headache, nausea and discomfort with treatment                                 |
| Alcohol                 |      |                                                  |                                                                        |                                                                                  |                    |                  |               |                           |                                                                          |                                                                                |
| Mishra et al. 2010      | 45   | Alcohol dependent, detoxified; inpatients. Participants received zolpidem and about ¾ of them received anticraving drugs. | Single blind, sham-controlled, parallel group trial (without randomization) | Craving measured by ACQ-NOW                                                      | 10 daily sessions  | Right DLPFC        | 10/110%       | 1000                     | Significant reduction in craving after the last rTMS session in the active group. | Transient headache and scalp pain in the active condition; seizure after the third sham-rTMS session. |
| Höppner et al. 2011     | 19   | Alcohol dependent; detoxified                    | Randomized, sham-controlled trial. Both groups were compared to a     | Craving measured by OCDS; attentional bias toward alcohol                         | 10                 | Left DLPFC        | 20/90%        | 1000                     | No significant between-group difference regarding craving and mood        | Not reported                                                                      |
female age-matched healthy control group and were exposed to neutral, emotional and alcohol-related pictures, before the first and after the last rTMS session. Stimuli measured by AB paradigm.

| Study                          | Participants | Design            | Craving Measure | Right DLPFC | Session Effect | Side Effect |
|-------------------------------|--------------|-------------------|-----------------|-------------|----------------|-------------|
| Herremans et al. 2012         | 36 Alcohol dependent; detoxified; hospitalized | Single-blind, sham-controlled design | Craving measured by OCDS | Right DLPFC | 20/110% | 1560 Lack of anticraving effects of a single session of high-frequency rTMS | Not reported |
| Cecenetti et al. 2015         | 18 Alcohol dependent, treatment seekers, detoxified | Between-subject randomized double-blind sham-controlled study | Blood cortisol and prolactin levels; Alcohol intake measured by TLFB; craving measured by VAS; | Medial PFC | 2/120% | NS Significant reduction in craving and drinking days following rTMS | Not reported |
| Herremans et al. 2015         | 26 Alcohol dependent; hospitalized | Single-blind, sham-controlled design followed by an open-label phase | Craving measured by TLS, AUQ and OCDS; | Right DLPFC | 20/110% | 1560 No decrease in cue-induced craving, but reduce in spontaneous craving | Scalp pain |
| Mishra et al. 2015            | 20 Alcohol dependent, treatment-seekers | Between-subject single-blind randomized study | Craving measured by ACQ-NOW; | Left and Right DLPFC | 10/100% | 1000 Significant reduction in craving in both conditions | Nightmare and middle insomnia in 1 case after rTMS over right DLPFC |
| Del Felice et al. 2016        | 17 Alcohol dependent; Hospitalized; in treatment with disulfiram | Single-blind sham-controlled trial | Neurophysiological effects measured by resting EEG records; Alcohol intake assessed with self-reports of number of drinks; craving measured by VAS; psychopathology symptoms severity assessed through SCL-90-R; response inhibition measured by numeric Stroop task and go/no-go task | Left DLPFC | 10/100% | 1000 No effect on craving and alcohol consumption. Positive effects on inhibitory control and selective attention | Not reported |

Continued
| Studies                        | N                        | Participants                                                                 | Design                                                                 | Outcomes measures                                                                                          | Number of sessions | Stimulation site | F (Hz)/% MT | Total pulses per session | Effects                                                                                           | Adverse events                                      |
|-------------------------------|--------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|---------------------|-------------------|----------------|------------------------------|---------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Addolorato et al. 2017        |                          | Alcohol dependent, treatment-seekers                                         | Double-blind randomized, sham-controlled, parallel group trial         | Striatal DAT availability assessed through SPECT; alcohol intake measured by TLFB; craving measured by OCDS; anxiety levels assessed through STAI Y1 and STAI Y2; depression symptoms measured by SDS | 4                   | Left and right DLPFC | 10/90%       | 2000            | Reduction in DAT availability and decrease in alcohol intake after rTMS sessions in the active group. | Reduction in DAT availability and decrease in alcohol intake after rTMS sessions in the active group. |
| Stimulants                    |                          |                                                                              |                                                                        |                                                                                                            |                     |                   |                |                              |                                                                                                   |                                                      |
| Camprodon et al. 2007         | 6                        | Cocaine dependent                                                          | Randomized, crossover study                                           | Craving measured by VAS                                                                                   | 2 (left or right side) | Left and Right DLPFC | 10/90%       | 2000            | Right but not left rTMS reduced craving                                                                 | Not reported                                          |
| Politi et al. 2008            | 36                       | Cocaine dependent                                                          | Open-label study                                                      | Craving measured through clinical evaluation                                                             | 10                  | Left DLPFC       | 15/100%      | 600             | Reduction in spontaneous craving                                                                 | Not reported                                          |
| Li et al. 2013                | 10                       | Not treatment-seeking, methamphetamine users                               | Single-blind, randomized, sham-controlled crossover study             | Craving measured by VAS after cue and neutral exposure                                                  | 2 (1Ac and 1S)      | Left DLPFC       | 1/NS          | 900             | Increase in craving by active rTMS                                                                  | Mild scalp discomfort at the start of both sham and active stimulation |
| Bolloni et al. 2016           | 10                       | Seeking outpatient treatment for cocaine use disorders                      | Double-blind randomized, sham-controlled, parallel group trial        | Cocaine intake assessed by hair analysis                                                               | 12                  | Bilateral PFC    | 10/100%      | 1000            | No effect on cocaine intake in the active group but long-term reduction on cocaine intake observed in active group when considered the time as factor | Mild headache after active stimulation               |
| Terraneo et al. 2016          | 32                       | Cocaine dependent, treatment-seekers                                        | Open-label, randomized study, rTMS or standard pharmacological treatment | Cocaine intake assessed by urine drug tests; craving measured by VAS; depressive symptoms assessed through depression subscale of the SCL-90 | 8                   | Left DLPFC       | 15/100%      | 2400            | Reduction in cocaine use and craving                                                                 | Mild discomfort at the start of stimulation          |
| Rapinesi et al. 2016          | 7                        | Cocaine dependent                                                          | Open-label study                                                      | Craving measured by VAS                                                                                   | 12                  | Left DLPFC       | 15/100%      | 720             | Significant reduction in craving following rTMS                                                   | Not reported                                          |
| Martinez et al. 2018          | 18                       | Actively users with cocaine use disorders                                   | Randomized, sham-controlled, parallel group trial                    | Cocaine-seeking behavior measured as the number of choices                                            | 15 (HF rTMS or LF rTMS) | mPFC and ACC      | 10/90%–110%  | 1200 (HF rTMS) 900 (LF rTMS) | Decreased cocaine self-administration in the high-aversive sensation associated                   | Aversive sensation associated                       |
| Study                | Patients | Treatment | Intervention Type                                                                 | Outcome Measures                                                                 |
|---------------------|----------|-----------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Su et al. 2017      | 30       | Methamphetamine addicted patients | Double-blind randomized, sham-controlled, parallel group trial | Craving measured by VAS; cognitive function assessed through CogState battery; depressive symptoms assessed by HAMD; Anxiety level evaluated by HAMA; subjective sleep quality assessed through PSQI |
|                     |          |           |                                                                                  | 5 Left DLPFC 10/80% 1200 Significant reduction in craving and improvement in verbal learning and memory and social cognition following rTMS in the active group |
| Liang et al. 2018   | 48       | Methamphetamine addicted patients | Double-blind randomized, clinical, parallel group intervention trial | Craving measured by VAS; withdrawal symptoms evaluated with methamphetamine; withdrawal symptom scale; subjective sleep quality assessed through PSQI; depressive symptoms assessed by self-rating depression scale; anxiety evaluated by self-rating anxiety scale; |
|                     |          |           |                                                                                  | 10 Left DLPFC 10/100% 2000 Significant reduction in craving and improvement in withdrawal symptoms, craving, quality of sleep, and mood status (depression and anxiety) after rTMS in the active group |
| Opiates             |          |           |                                                                                  |                                                                                  |
| Shen et al. 2016    | 20       | Heroin dependent, detoxified     | Randomized, sham-controlled crossover study | Craving measured by VAS |
|                     |          |           |                                                                                  | 2 (1Ac and 1S) Left DLPFC 10/100% 2000 Reduction in cue-induced craving by active rTMS |
| Sahlem et al. 2017  | 13       | Non-treatment seeking opiate dependents | Randomized, counterbalanced crossover study | Craving measured by VAS |
|                     |          |           |                                                                                  | 1 Left DLPFC 10/110%–120% 3000 Reduction in cue-induced craving by active rTMS |

(Ac) active, (S) sham, (DLPFC) dorsolateral prefrontal cortex, (SFG) superior frontal gyrus, (mPFC) medial prefrontal cortex, (ACC) anterior cingulate cortex, (HF rTMS) high-frequency rTMS, (LF rTMS) low-frequency rTMS, (cTBS) continuous theta burst stimulation, (VAS) visual analog scale, (FTND) Fagerström test for nicotine dependence, (STCQ) Tobacco Craving Questionnaire—short version, (QSU-Brief) Questionnaire on Smoking Urges—Brief, (ACQ-NOW) Alcohol Craving Questionnaire, (OCDS) Obsessive Compulsive Drinking Scale, (AB) attentional blink, (TLFB) time line follow back method, (TLS) ten-point Likert scales, (AUQ) Alcohol Urge Questionnaire, (SCL-90-R) Symptom Check List—Revised, (DAT) dopamine transporter, (SPECT) single-photon emission computed tomography, (SDS) Zung Self-Rating Depression Scale, (HAMAI) Hamilton depression scale, (HAMAS) Hamilton anxiety scale, (PSQI) Pittsburgh Sleep Quality Index, (DAGS) Dannon and Ainhold Gambling Scale, (Y-BOCS) Yale–Brown Obsessive Compulsive Scale, (PG-YBOCS) Yale–Brown Obsessive Compulsive Scale Adapted for Pathological Gambling, (GACS) Gambling Craving Scale.
naries, and patient sample features. All together this variability may account for conflicting clinical outcomes. Therefore, double-blind sham-controlled and long-term follow-up studies are necessary to test the efficacy, tolerability, and safety of rTMS in addicted populations. These studies will also allow us to understand how neuromodulatory therapies can be further improved. Developing novel TMS protocols can allow us to achieve stronger and more persistent long-term neuromodulation. Moreover, stimulation of different and deeper brain areas may be pursued with advanced coils (e.g., H-coils) that have less attenuation of the electromagnetic field with depth and thus target other key areas involved in addiction pathophysiology. A better knowledge of mechanisms and factors underlying the aftereffects that TMS induces can potentially allow us to tailor TMS parameters on the individual physiology of the patient. When pursuing rTMS as a potential treatment, one should also consider advances in neuroimaging and neurophysiology investigations in the attempt to biotype addicted individuals and identify biomarkers predicting the treatment response.

REFERENCES

Addolorato G, Antonelli M, Cocciofallo F, Vassallo GA, Tarli C, Sestito L, Mirijello A, Ferrulli A, Pizzuto DA, Camardese G, et al. 2017. Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake. Eur Neuropsychopharmacol 27: 450–461. doi:10.1016/j.euroence.2017.03.008

American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, Arlington, VA.

Amiaz R, Levy D, Vainiger D, Grunhaus L, Zangen A. 2009. Recruiting cocaine-induced prefrontal cortex hypoactivity prevents compulsive cocaine seeking. Nature 496: 359–362. doi:10.1038/nature12024

Chen J, Tan Z, Zeng L, Zhang X, He Y, Gao W, Xu X, Li Y, Bu B, Wang W, et al. 2013b. Heterosynaptic long-term depression mediated by ATP released from astrocytes. Glia 61: 178–191. doi:10.1002/glia.22425

Chernyavsky AV, Chernyavsky AV, Sinitsyn DS, Piradov MA. 2015. Possible mechanisms underlying the therapeutic effects of transcranial magnetic stimulation. Front Hum Neurosci 9: 303. doi:10.3389/fnhum.2015.00303

Cho SS, Strafella AP. 2009. rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One 4: e6725. doi:10.1371/journal.pone.0006725

Cirillo G, Di Pino G, Capone F, Ranieri F, Florio L, Todisco V, Tedeschi G, Funke K, Di Lazzaro V. 2017. Neurobiological after-effects of non-invasive brain stimulation. Brain Stimul 10: 1–10. doi:10.1016/j.brs.2016.11.009

Cohen H, Kaplan Z, Kotler M, Kouperman I, Moisa R, Grisaru N. 2004. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. Am J Psychiatry 161: 515–524. doi:10.1176/appi.ajp.161.3.515

Del Felice A, Bellamoli E, Formaggio E, Manganotti P, Masiero S, Cuoghi G, Rimondo C, Genetti B, Sperotto M, Corso F, Cassel K, Downs BW, Waite RL, Williams L, et al. 2008. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model 5: 24. doi:10.1186/1742-4682-5-24

Bolloni C, Panella R, Pedetti M, Frascella AG, Gambelunghe C, Battistutta D, Capone F, Dileone M, Oliviero SH, Cassel K, Downs BW, Waite RL, Williams L, et al. 2008. Bilateral transcranial magnetic stimulation of the prefrontal and infrasplenial cortices. Eur J Neurosci 19: 1950–1962. doi:10.1111/j.1460-9588.2004.03277.x

Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, et al. 2008. Activation instead of blocking mesolimbic dopaminergic re-ward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model 5: 24. doi:10.1186/1742-4682-5-24

Bolloni C, Panella R, Pedetti M, Frascella AG, Gambelunghe C, Piccoli T, Maniaci G, Brancato A, Cannizzaro C, Diana M. 2014. Activation of corticospinal neurons and spinal motor neurons of the spinal cord of the anaesthetized monkey. Exp Brain Res 232: 283–290. doi:10.1139/cpp-2014-0188

Boh Eichhammer P, Languth B, Marienhagen J, Kleinnung T, Hajak G. 2003. Neuronavigated repetitive transcranial magnetic stimulation in patients with tinnitus: a short case series. Biol Psychiatry 54: 862–865. doi:10.1016/S0006-3223(02)01896-6

Etievant A, Manta S, Latapy C, Magno LA, Fectueix S, Beaujou J-M. 2015. Repetitive transcranial magnetic stimulation induc-
es long-lasting changes in protein expression and histone acetylation. *Sci Rep* **5**: 16873. doi:10.1038/srep16873

Ettin EB, Rothwell JC, Wise D RW. 2005. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. *Nat Neurosci* **8**: 1481–1489. doi:10.1038/nrn1579

Feil J, Zangen A. 2010. Brain stimulation in the study and treatment of addiction. *Neurosci Biobehav Rev* **34**: 559–574. doi:10.1016/j.neubiorev.2009.11.006

Feltenstein MW, See RE. 2009. The neurocircuity of addiction: an overview. *Br J Pharmacol* **154**: 261–274. doi:10.1038/bjp.2008.51

Gamboa OL, Antal A, Molináde V, Paulus W. 2010. Simply longer is not better: reversal of theta burst after-effect with prolonged stimulation. *Exp Brain Res* **204**: 181–187. doi:10.1007/s00221-010-2293-4

George O, Koob GF. 2010. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. *Neurosci Biobehav Rev* **35**: 232–247. doi:10.1016/j.neubiorev.2010.05.002

Goldstein RZ, Volkow ND. 2002. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. *Am J Psychiatry* **159**: 1642–1652. doi:10.1176/appi.ajp.159.10.1642

Goldstein RZ, Volkow ND. 2011. Dysfunction of the prefrontal cortex function and connectivity: neuroimaging findings and clinical implications. *Nat Rev Neurosci* **12**: 652–669. doi:10.1038/nrn3119

Haddiy D, Anderson BS, Borckardt JJ, Arana A, Li X, Nahas Z, George MS. 2011. Safety, tolerability, and effectiveness of high doses of adjunctive left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. *J ECT* **27**: 18–25. doi:10.1097/YCT.0b013e182ac106c

Hallett M. 2000. Transcranial magnetic stimulation and the human brain. *Nature* **406**: 147–150. doi:10.1038/35018000

Hanlon CA, Dowdle LT, Austelle CW, Devries W, Mithoefer O, Manis MA, Mitterer O, Antal A, Moliadze V, Paulus W. 2010. Simply long-lasting changes in protein expression and histone acetylation. *CIRCUITS-BASED TREATMENT FOR ADDICTION* **183**: 141–152. doi:10.1097/YCT.0b013e182a5559d4

Höppner J, Broese T, Wendler L, Berger C, Thome J. 2011. Repetitive transcranial magnetic stimulation (rTMS) for treatment of alcohol dependence. *World J Biol Psychiatry* **12**: 57–62.

Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. 2005. Theta burst stimulation of the human motor cortex. *Neuroreport* **45**: 201–206. doi:10.1016/j.neuro.2004.12.033

Ilmoniemi RJ, Kiéć D. 2010. Methodology for combined TMS and EEG. *Brain Topogr* **22**: 233–248. doi:10.1007/s10548-009-0123-4

Ilmoniemi RJ, Virtanen J, Ruohonen J, Karhu J, Aronen HJ, Näätänen R, Katila T. 1997. Neuronal responses to magnetic stimulation reveal cortical reactivity and connectivity. *Neuroreport* **8**: 3537–3540. doi:10.1097/00001756-199711100-00024

Ilmoniemi RJ, Ruohon J, Breshears B, Inglis P. 2005. Transcranial magnetic stimulation—a new tool for functional imaging of the brain. *Critt Rev Biomed Eng* **27**: 241–284.

Jackson MP, Rahman A, Lafon B, Kronberg G, Ling D, Parra LC, Bikson M. 2010. Animal models of transcranial direct current stimulation: methods and mechanisms. *Clin Neurophysiol* **127**: S425–S454. doi:10.1016/j.clinph.2010.08.016

Johnston M, Wiegand R, Khamis A, Bobb G, Sommer G, Hajak G, Wodarz N, Eichhammer P. 2003. [Transcranial magnetic stimulation for nicotine dependence]. *Psychiatr Prax* **30**: S129–S131. doi:10.1055/s-2003-39733

Jovanovski D, Erb S, Zakanzis KK. 2005. Neurocognitive deficits in cocaine users: a quantitative review of the evidence. *J Clin Exp Neuropsychol* **27**: 189–204. doi:10.1080/138033904456094

Katzas PW, O’Brien C. 2008. Drug addiction as a pathology of staged neuroplasticity. *Neuropsychopharmacology* **33**: 166–180. doi:10.1038/sj.ner.5501564

Kanno M, Matsumoto M, Togashi H, Yoshioka M, Mano Y. 2003. Effects of repetitive transcranial magnetic stimulation on behavioral and neurochemical changes in rats during an elevated plus-maze test. *J Neurosci* **211**: 5–14. doi:10.1016/S0022-510X(03)00030-3

Karanabanov A, Ziemann U, Hamada M, George MS, Quartarone A, Classen J, Massimini M, Rothwell J, Siebner HR. 2015. Consensus paper: probing homeostatic plasticity of human cortex with non-invasive transcranial brain stimulation. *Brain Stimul* **8**: 993–1006. doi:10.1016/j.brs.2015.06.017

Kenny PJ, Hoyer D, Koob GF. 2018. Animal models of addiction and neuropsychiatric disorders and their role in drug discovery: honoring the legacy of Aithana Markou. *Biol Psychiatry* **83**: 940–946. doi:10.1016/j.biopsych.2018.02.009

Kling JW, Yarita M, Yamamoto T, Matsumiya Y. 1990. Conditioned taste aversions is diminished by transcranial magnetic stimulation. *Physiol Behav* **48**: 713–717. doi:10.1016/0031-9384(90)90216-Q

Kosh GF, Volkow ND. 2010. Neurocircuity of addiction. *Neuropsychopharmacology* **35**: 217–238. doi:10.1038/npp.2009.110

Labruna L, Jamil A, Fresnoza S, Batsikadze G, Kuo M-F, Van der Velden B, Ivory RB, Nitsche MA. 2016. Efficacy of anodal transcranial direct current stimulation is related to sensitivity to transcranial magnetic stimulation. *Brain Stimul* **9**: 8–15. doi:10.1016/j.brs.2015.08.014

Lanza G, Cantone M, Lanuzza B, Pennisi M, Bella R, Pennisi G, Ferri M. 2015. Distinctive patterns of cortical excitability to transcranial magnetic stimulation in obstructive sleep apnea syndrome, restless legs syndrome, insomnia, and sleep deprivation. *Sleep Med Rev* **19**: 39–50. doi:10.1016/j.smrv.2014.04.001

Lenz M, Platschek S, Priesemann V, Becker D, Willems LM, Ziemann U, Deier T, Müller-Dahlhaus F, Jedicka V, Vlachos A. 2015. Repetitive magnetic stimulation induces plasticity of excitatory postsynaptic on proximal dendrites of cultured mouse CA1 pyramidal neurons. *Brain Struct Funct* **220**: 3323–3337. doi:10.1007/s00429-014-0859-9

Levy D, Shabat-Simon M, Shalev U, Barnea-Ygael N, Cooper A, Zangen A. 2007. Repeated electrical stimulation of reward-related brain regions affects cocaine but not “natural” reinforcement. *J Neurosci* **27**: 14179–14189. doi:10.1523/JNEUROSCI.4477-07.2007

Li X, Hartwell KJ, Owens M, Lernatty T, Borckardt JJ, Hanlon CA, Brady KT, George MS. 2013. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. *Biol Psychiatry* **73**: 714–720. doi:10.1016/j.biopsych.2013.01.003

Liang Y, Wang L, Yuan T-FF. 2018. Targeting withdrawal symptoms in men addicted to methamphetamine with transcranial magnetic stimulation: a randomized clinical trial. *JAMA Psychiatry* **75**: 1199–1201.

Martínez D, Urban N, Grassetti A, Chang D, Hu M-C, Zangen A, Levin FR, Foltin R, Nunes EV. 2018. Transcranial magnetic
